Acarix is a company that develops medical devices for the treatment of coronary artery disease (CAD). It offers the Acarix CADScorSystem, a device that records and processes heart sounds. The system detects turbulent arterial flow and myocardial movement and provides a CAD-score on the screen.

Acarix AB engages in the provision of medical devices for monitoring Coronary Artery Disease. It develops and commercializes diagnostic tests based on its technology platform CADScor System. The

1 vecka. Acarix AB operates as a medical technology company which is engaged in developing diagnostic tests for cardiovascular diseases primarily in Europe, China, and the United States. Its main activities are to develop, produce and market a new cardiovascular diagnostic method and similar equipment for the same and related services. Acarix AB is a Sweden-based provider of diagnostic solutions for coronary artery disease (CAD). The Company’s primary product CADScor System features phonocardiography technique and algorithms. The CADScor System is fixed with a specific patch to the chest of the patient, with the recording head placed at the forth left intercostal space, and the sensor resting on the sternum. 2019-03-14 AcariX.

Acarix

Acarix är ett medicintekniskt bolag i tidig kommersialiseringsfas och är en tidigare avknoppning från danska medtech-jätten Coloplast. Acarix arbetar med att förändra och effektivisera den diagnostiska vårdkedjan för hjärt- och kärlsjukdomar som idag innebär att många patienter tvingas genomgå invasiva och i många fall hälsovådliga undersökningar i onödan. Acarix planerar en Acarix A/S is based on pioneering research performed at the Aalborg University, Denmark, initiated in 2004. The CADScor system is designed to significantly decrease the cost of the Coronary Artery Disease diagnostic pathway by lowering the evaluation cost. Business Areas: Diagnostics, Cardiovascular Acarix AB operates as a medical technology company which is engaged in developing diagnostic tests for cardiovascular diseases primarily in Europe, China, and the United States. Its main activities are to develop, produce and market a new cardiovascular diagnostic method and similar equipment for the same and related services.

Magic Formula. Investeringsstrategin är baserad på Joel Greenblatts "En liten bok som slår aktiemarknaden”. Med ”Acarix” eller ”Bolaget” avses, beroende på sammanhanget, Acarix AB, org.nr.

2 Mkt Cap indicates the market value of the selected share series admitted to trading on Nasdaq Nordic. Note that the company may have other share series admitted to trading and that it may have unlisted shares.

Business Areas: Diagnostics, Cardiovascular Acarix AB operates as a medical technology company which is engaged in developing diagnostic tests for cardiovascular diseases primarily in Europe, China, and the United States. Its main activities are to develop, produce and market a new cardiovascular diagnostic method and similar equipment for the same and related services.

Acarix AB (Malmö, Sweden) is a medical device company bringing cardiac screening tools to the GP’s practice. Acarix is a Swedish MedTech company founded in 2009, marketing the CADScor®System – the innovative, non-invasive and ultra-sensitive analytical device designed to support a safe, reliable and cost-effective rule-out of significant coronary

Acarix AB engages in the provision of medical devices for monitoring Coronary Artery Disease. It develops and commercializes diagnostic tests based on its technology platform CADScor System. The company was founded by Peter Boman Samuelsen, Samuel Schmidt, Weimin Rong and Claus Bo VÃ¶ge Christensen in 2009 and is headquartered in Malmo, Sweden.

Bolaget hade då en omsättningstillväxt på 55,4 %. Acarix vinstmarginal låg vid senaste årsbokslutet på -575,6 % vilket ger Acarix placeringen 395 103 i Sverige av totalt 626 959 aktiebolag. Få detaljerad information om Acarix A/S (ACARIX) aktie inklusive kurs, diagram, tekniska analyser, empirisk data, Acarix rapporter och mycket mer. Acarix | 717 följare på LinkedIn. The CADScor®System Designed to improve patient care | Acarix is a Swedish MedTech company founded in 2009, marketing the CADScor®System – the innovative, non-invasive and ultra-sensitive analytical device designed to support a safe, reliable and cost-effective rule-out of significant coronary artery disease (CAD) at the very first stage of the diagnostic Acarix AB på First North gör en nyemission på 56 Mkr. Prospekt och teckningssedel för att investera i aktie. Värdering och villkor Acarix AB gick med förlust (2019) Acarix AB gick med förlust, -45 855 000 kr.
Lynx dynamic devices

Acarix has recently received market approval for CADScor in the US, […] 2021-04-12 · Kallelse till årsstämma i Acarix AB. Aktieägarna i Acarix AB, org. nr 559009-0667, ("Bolaget") kallas härmed till årsstämma tisdagen den 11 maj 2021.

Ryvangs Alle 81-83. DK-2900 Hellerup. Denmark. Re: DEN190047.
Svala björgvinsdóttir

acarix · Acarix initiates multi-center trial · Acarix receives commercial order for CADScorSystem · Acarix awarded Design award · Well-oversubscribed share issue for

ACARIX: STYRELSELEDAMOT KÖPER AKTIER FÖR KNAPPT 0,9 MLN KR; 2021-04-07 10:47 · Nyhetsbyrån Direkt ACARIX: LÅNGTIDSDATA FRÅN DAN-NICAD 1-STUDIEN I TIDSKRIFT; 2021-04-07 10:40 · GlobeNewswire Positive, long term prognostic data from the Dan-NICAD I study published in European Heart Journal- Digital Health; 2021-04-07 10:40 · GlobeNewswire Acarix är en förkortning för Acoustic Cardiac Diagnostics och bolaget grundades 2009 som en avknoppning från Coloplast. Huvudkontoret ligger i Malmö. Verkställande direktör: Per Persson Acarix har utvecklat ett elektroniskt stetoskop som avlyssnar genomströmningen i hjärtats kranskärl och som indikerar om det finns risk för förträngning.